Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

Marker Therapeutics, Inc.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Ian Laing

James Noble

Adaptimmune Therapeutics plc

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Isaac Ciechanover

Atara Biotherapeutics, Inc.

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Celyad Oncology SA

Marker Therapeutics is engaged in developing novel T-cell therapies targeted at blood cancers and solid tumors. The company's proprietary Multi-Antigen Recognizing (MAR) T cell technology allows for the recognition and targeting of tumor cells without genetic modifications, with a focus on safety and efficacy in various clinical indications.

Marker Therapeutics

Marker Therapeutics, Inc. | 4,075 followers on LinkedIn. Pioneering a Multi-Antigen Approach | We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s unique cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize multiple tumor associated antigens (multiTAA) and kill tumor cells expressing those targets. Once infused into patients, this population of multiTAA-specific T cells attacks multiple tumor targets and acts to activate the patient’s immune system to produce broad spectrum anti-tumor activity.

Wilson Wolf CEO focused on solving cell and gene therapy manufacturing challenges

John Wilson

Senior Human Resources Manager at Marker Therapeutics, Inc.

Nina Sisommout, SHRM-CP

Clinical Project Manager at Marker Therapeutics

Molly Gilbert

Immunologist/Cancer Biologist

Laura S Angelo

📢 Today we reported our third quarter 2024 financial results and provided business updates. Follow the link for more information: https://lnkd.in/g-bjC4Jt #multiTAA #immunotherapy #ClinicalTrials #CellTherapy #patients #cancer #biotech #lymphoma #AML #PancreaticCancer

📢 Today we reported our second quarter 2024 financial results and provided business updates. Follow the link for more information: https://lnkd.in/gDjQfatn #multiTAA #immunotherapy #ClinicalTrials #CellTherapy #patients #cancer #biotech #lymphoma #AML #PancreaticCancer

NEWS 💥 NEWS 💥 NEWS! Marker Therapeutics was awarded a $2 million grant from the #NIH Small Business Innovation Research ( #SBIR ) program! ✨ The proceeds of this award will support our Phase 1 APOLLO study, investigating the #safety and #efficacy of MT-601 in patients with non-Hodgkin’s lymphoma who have relapsed following anti-CD19 CAR-T cell therapy. For more information: https://lnkd.in/gHPjgKUf #immunotherapy #CART #multiTAA #ClinicalTrials #CellTherapy #lymphoma #patients #cancer #biotech

Today we announced that Dr. Shouse, the Principal Investigators at City of Hope , was invited to present his experience from our clinical study in patients with #lymphoma (APOLLO study) at the 11th Global Summit on Hematologic Malignancies. Marker’s Phase 1 #APOLLO study is investigating MT-601, a #multiTAA -specific T cell product, for the treatment of patients with #lymphoma who have #relapsed or are #ineligible to receive #CAR T cell therapy. Key Highlights: 🌟 Three patients were treated at City of Hope as part of the #APOLLO study. 🌟 First study participant treated with MT-601 had diffuse large B cell lymphoma (DLBCL) and failed 4 prior lines of therapy, including a relapse within 90 days of CAR T cell therapy. This participant achieved a #CompleteResponse 8 weeks after the second infusion of MT-601 and remains in complete response #9 #months after initial treatment with MT-601. 🌟 Another study participant was diagnosed with follicular lymphoma that transformed into DLBCL. This participant failed 12 lines of therapy, including CAR T cells. 8 weeks after treatment with MT-601, the study participant achieved a #CompleteResponse , which is maintained 3 months following initial treatment with MT-601. 🌟 The third study participant treated at City of Hope had DLBCL with cutaneous involvement and was not eligible for CAR T cell therapy. This participant achieved a #PartialResponse 8 weeks after MT-601 treatment with all lesions decreasing in size including one that has completely resolved. 🌟 Treatment was well tolerated among all patients with no significant treatment-related adverse events. For more information: https://lnkd.in/gVgUburj #immunotherapy #CART #multiTAA #ClinicalTrials #CellTherapy #lymphoma #patients #cancer #biotech

Join our CEO Juan Vera and learn more about Marker’s #multiTAA T cell products and clinical studies. 📅 Date: March 26, 2024 ⏰ Time: 10:00 AM, EDT Don’t miss out! Your virtual seat awaits here: https://lnkd.in/dx_JUSBm During the conference, our team will conduct one-on-one meetings with registered investors to discuss clinical developments, recent achievements, and anticipated milestones. For more information: https://lnkd.in/gkC_h5Uf #immunotherapy #ClinicalTrials #CellTherapy #patients #cancer #biotech #lymphoma #AML #PancreaticCancer

We are thrilled to present at the H.C. Wainwright & Co., LLC 2nd Annual Cell Therapy Virtual Conference on March 26, 2024! Join our CEO Juan Vera and learn more about Marker’s #multiTAA T cell products and clinical programs. 📅 Date: March 26, 2024 🕙 Time: 10:00 AM, EDT 👉 Register here: https://lnkd.in/dSQTZqkm The presentation will be available for replay starting March 26, 2024 on the Company’s IR website under Events & Presentations. During the conference, our team will conduct one-on-one meetings with registered investors to discuss clinical development, recent achievements, and anticipated milestones. For more information: https://lnkd.in/gkC_h5Uf #immunotherapy #ClinicalTrials #CellTherapy #patients #cancer #biotech #lymphoma #AML #PancreaticCancer

💥 Breaking News! Today we announced that the United States Adopted Names ( #USAN ) Council and the World Health Organization ( #WHO ) International Nonproprietary Names ( #INN ) expert committee approved “neldaleucel” as the nonproprietary (generic) name for MT-601, our #multiTAA -specific T cell product candidate for the treatment of patients with #lymphoma . Follow the link for more information: https://lnkd.in/gnjjXXvB #immunotherapy #ClinicalTrials #CellTherapy #patients #cancer #biotech

📢 Exciting News! Today we announced clinical program updates! Key Highlights: 🌟 Strategic prioritization of clinical programs with a focus on MT-601 in CAR relapse patients with #lymphoma based on promising non-clinical and clinical data. 🌟 Promising clinical observations and new directions with MT-401 in patients with #MRD (measurable residual disease) in #AcuteMyeloidLeukemia (AML). For more information click here: https://lnkd.in/gKyPUKeN #immunotherapy #multiTAA #ClinicalTrials #CellTherapy #patients #cancer #biotech #PancreaticCancer

Meet us in San Francisco during J.P. Morgan week from January 8-10! We are excited to kick off the new year with #JPM ! ✨ If you are attending #JPM2024 and want to connect with our team, please contact us. #SanFrancisco #multiTAAs #biotech #innovation #cancer #immunotherapy #AML #lymphoma #healthcare

We are honored to be recognized as part of the 2023 FreeMind Elite! 🌟 The FreeMind Elite is a selection of FreeMind Group clients who have excelled in securing non-dilutive funding and developing medical technologies in the life sciences sector over the past year. Thank you FreeMind Group for this recognition and our existing partnership! 🎉🙌 #FreeMindElite #immunotherapy #multiTAA #ClinicalTrials #CellTherapy #lymphoma #AML #patients #cancer #biotech

Metric
Company Name	Marker Therapeutics, Inc.	Adaptimmune Therapeutics plc	Atara Biotherapeutics, Inc.	Celyad Oncology SA
Symbol	MRKR	ADAP	ATRA	CYAD
MSH ID	COM:MARKERTHERAPEUTICS	COM:ADAPTIMMUNE	COM:ATARABIO	COM:CELYAD
Market	STOCKS	STOCKS	STOCKS	STOCKS
Sector	Healthcare	Healthcare	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	US	GB	US	BE
Stage	Grant
Employee Count	8	449	173	17
Website	markertherapeutics.com	adaptimmune.com	atarabio.com	celyad.com
LinkedIn	marker-therapeutics		atarabio
Founders

Metric
Market Cap	44.42M	293.91M	44.24M	11.77M
Enterprise Value
Monthly Web Traffic	4.75K		3.75K
Web Traffic Growth	-0.22		-0.55
Valuation
Raised Capital	2M

Metric
Revenue	3.31M	60.51M	8.57M	107.74K
Revenue (LTM)
Revenue (NTM)
Gross Profit	3.31M	50.66M	-313K	34.86K
EBITDA	-14.58M	-127.91M	-264.45M	-11.19M
Operating Income	-14.58M	-137.77M	-269.28M	-11.19M
Net Income	-16.97M	-114.31M	-276.13M	-8.92M
EPS	-1.93	-0.57	-2.61	-0.35
Diluted EPS	-1.93	-0.57	-2.61	-0.35
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.36	0.94	0.80	0.53
Operating Profit Margin	-1.54	-0.57	-2.68	-103.22
EBITDA Margin	-4.40	-2.11	-30.85	-103.89
Net Profit Margin	-0.88	-0.51	-2.90	-82.82
Return on Equity	-0.36	-1.17	20.16	5.42
Return on Assets	-0.40	-0.23	-1.41	-0.52
Return on Capital Employed	-0.97	-0.34	14.32	-0.75

COM:MARKERTHERAPEUTICS

Marker Therapeutics

Last Close

2.97

22/11 21:00

Market Cap

44.42M

Beta: -

Volume Today

11.73K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-4.26	-1.68	-0.42	-0.22
P/B Ratio	2.38	1.81	-2.42	2.09
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	15.58	19.34	19.51	329.55
EV Multiple	-2.73	-1.57	0.15	0.12

Metric
Days Sales Outstanding	2.88	4.05	13.10
Days Payables Outstanding	249.06		415.04
Days Inventory Outstanding	0.00	49.24	552.47	14.05K
Operating Cycle	243.84	574.38	1.85K	17.39K
Cash Conversion Cycle	243.84	352.12	1.70K	16.02K
Asset Turnover	0.54	0.44	0.53	0.01

Metric
Operating Cash Flow	-16.44M	-141.43M	-192.98M	-16.06M
Free Cash Flow	-16.44M	-146.32M	-194.20M	-17.04M
Cash Flow to Debt	8.84	-1.47	-2.78	-0.91
Operating Cash Flow/Sales	-1.93	-0.31	-2.11	-134.75
Free Cash Flow Yield	-0.51	-0.49	-1.34	-2.65

Metric
Cash & Equivalents	15.11M	143.99M	25.84M	7.40M
Accounts Receivable	1.37M	-1.30M	6.11M
Inventory	1		9.71M
Goodwill
Debt to Capitalization		0.49	5.64	2.60
Debt to Assets	-0.12	0.09	0.33	0.01
Current Ratio	7.01	2.92	1.50	1.42
Quick Ratio	6.32	3.09	1.30	3.79

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.14	0.18	10.31
R&D to Revenue	1.60	1.64	52.33
SG&A to Revenue	0.79	1.01	11.60